Drug Profile
Farudodstat - ASLAN Pharmaceuticals
Alternative Names: ASLAN-003; LAS 186323Latest Information Update: 18 Apr 2024
Price :
$50
*
At a glance
- Originator Laboratorios Almirall
- Developer Almirall S.A.; ASLAN Pharmaceuticals
- Class Aniline compounds; Antineoplastics; Antirheumatics; Antivirals; Carboxylic acids; Fluorobenzenes; Phenyl ethers; Pyridines; Skin disorder therapies; Small molecules
- Mechanism of Action Dihydroorotate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alopecia areata
- Phase I Multiple sclerosis
- Preclinical COVID 2019 infections; Dengue; Zika virus infection
- No development reported Rheumatoid arthritis
- Discontinued Acute myeloid leukaemia
Most Recent Events
- 12 Apr 2024 Adverse events data from a phase IIa FAST-AA trial in Alopecia areata released by ASLAN Pharmaceuticals
- 01 Mar 2024 ASLAN Pharmaceuticals has patents pending for farudodstat in European Union
- 15 May 2023 Pharmacodynamics data from a preclinical trial in Alopecia areata released by ASLAN Pharmaceuticals